A Venture Capital firm with offices in the USA closed their first fund in 2014 and is currently working on their second fund. The firm has approximately 40 active investments in the biotech space. The firm mostly invests in Seed to Series B primarily but has and will consider later stage funding depending upon the merits of each deal structure. The firm will consider a seed investment of $250k – $1 million for Seed. Typical funding sizes for Series A & B are dependent upon the deal but generally $5 million and beyond. The firm is open to investing in companies worldwide and remain agnostic to space and disease.
The firm invests exclusively in the Life Science space and is looking for new investment opportunities in the therapeutics, medical devices, diagnostics, and selective digital health sectors. The firm is opportunistic in terms of sub-sectors and indications, including all classes of medical devices, as well as all phases of development for therapeutics.
The firm is open to all types of management teams but like to see highly motivated entrepreneurs who are looking to lead monumental healthcare change and with management teams that have serial startup drives with whom they can build long term partnerships. The firm is open to both leading, co-leading, or participating in syndicates depending on the company and deal structure.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply